Pediatric renal transplantation: A single center experience over 14 years
- 21 October 2005
- journal article
- Published by Wiley in Pediatric Transplantation
- Vol. 10 (2) , 193-197
- https://doi.org/10.1111/j.1399-3046.2005.00423.x
Abstract
Between 1989 and 2003, 100 transplants were performed in 96 patients at the pediatric nephrology unit of the Calvo Mackenna Children's Hospital. Mean age 10.9 ± 3.9 yr (1–17.6), 30% from LD. Donors were younger than 5 yr in five patients and all recipients received an ‘en bloc’ graft. Original disease was hypo/dysplasia 27%, reflux nephropathy 22 and 17% chronic glomerulonephritis. The immunosuppressive protocol during the first period (n = 56, 1989–2000): Cyclosporine, steroids and azathioprine, and during the second period (n = 44, 2001–2003): FK, steroids, MMF and anti‐CD25 antibody (mAbs). AR was reported in 22 patients, 11% in LD, 31% in DD (p < 0.01). The AR rate decreased from 40 to 8% after anti‐CD25 monoclonal induction. Patient actuarial survival rate at 1, 3 and 5 yr was 100% for LD and 96% for DD. The overall actuarial graft survival at 1,3, and 5 yr was 96.7, 96.7 and 71% for LD and 89, 76 and 73% for DD donors. Graft survival rate improved from the first period (1989–2000) to the second period (2001–2003; p = 0.05). No difference in graft survival rate with HLA‐A,B,DR matching was found. Graft survival rate was better when cold ischemia time was Z score at 1, 3 and 5 yr post‐transplant was −2.2, −2.1, −2.2, respectively, for children older than 7 yr and −1.8, −1.9, −2.1 for those transplanted younger than 7 yr of age who were switched to alternate day steroids (p < 0.01). The cause of graft lost was: chronic rejection eight, non‐adherence four, AR four and vascular thrombosis two. The cause of death in two patients was fungus septicemia and accelerated rejection. Pediatric renal transplantation can be performed in our group with acceptable morbidity, low mortality and graft survival rates similar to other reports in North America and Western Europe. Graft survival rate improved with newer immunosuppression and greater experience at the center. Management of non‐adherence and chronic rejection remain the major challenges.Keywords
This publication has 14 references indexed in Scilit:
- Racial and Center Differences in Hemodialysis Adequacy in Children Treated at Pediatric CentersJournal of the American Society of Nephrology, 2004
- Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation1Transplantation, 2003
- A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipientsTransplantation, 2002
- Single centre experience with basiliximab in paediatric renal transplantationNephrology Dialysis Transplantation, 2002
- Efficacy and tolerability of interleukin‐2 receptor blockade with basiliximab in pediatric renal transplant recipientsPediatric Transplantation, 2001
- Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipientsPediatric Transplantation, 2000
- PREDNISONE WITHDRAWAL IN KIDNEY TRANSPLANT RECIPIENTS ON CYCLOSPORINE AND MYCOPHENOLATE MOFETIL-A PROSPECTIVE RANDOMIZED STUDY1,2Transplantation, 1999
- Center volume effects in pediatric renal transplantationPediatric Nephrology, 1999
- URINARY TRACT INFECTION IN THE IMMUNOCOMPROMISED HOSTInfectious Disease Clinics of North America, 1997
- Renal Transplantation in ChildrenNephron, 1987